Wednesday January 31, 2024
Clinical development update
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Clinical development update Positive Results from XF-73 Dermal Safety Study XF-73 Dermal to be progressed towards clinical evaluation for the treatment of […]
Monday January 22, 2024
Appointment of Nominated Adviser and Sole Broker
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Appointment of Nominated Adviser and Sole Broker Brighton, United Kingdom ‐ 22 January 2024 ‐ Destiny Pharma (AIM: DEST), a clinical stage […]
Thursday January 4, 2024
Year End Business Update
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Year End Business Update Brighton, United Kingdom – 4 January 2024 – Destiny Pharma plc (AIM:DEST), a clinical stage biotechnology company focused on the […]
Tuesday October 17, 2023
XF Pipeline Update Meeting
Destiny Pharma plc (“Destiny Pharma” or “the Company”) XF Pipeline Update Meeting with Leading Experts and New Microbiological Data on XF-73 Brighton, United Kingdom – 17 October 2023 – Destiny […]
Tuesday October 17, 2023
Publication of new microbiological data for XF-73
Destiny Pharma plc (“Destiny Pharma” or “the Company”) New publication shows XF‐73 drug potent against 2,527 Staphylococcus isolates Largest study of its kind to date demonstrates effectiveness of XF‐73 against […]
Tuesday July 25, 2023
Appointment of new Chairman
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Appointment of new Chairman Brighton, United Kingdom – 25 July 2023: Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on […]
Tuesday May 2, 2023
Positive results from SPOR-COV® research
Destiny Pharma and SporeGen® announce update from research collaboration under Innovate UK grant award to develop a biotherapeutic treatment (SPOR-COV®) for COVID-19 and Influenza Positive results from testing SPOR-COV in […]
Wednesday April 26, 2023
Posting of Annual Report and Accounts, and Notice of AGM
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Posting of Annual Report and Accounts, and Notice of AGM Brighton, United Kingdom – 26 April 2023 – Destiny Pharma plc (AIM: DEST) […]
Thursday April 13, 2023
Audited results for year ended 31 December 2022
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Audited results for the year ended 31 December 2022 Exclusive North American partnering deal worth up to $570m plus royalties secured for […]
Tuesday April 4, 2023